Concurrent low-dose radiation and durvalumab and etoposide/platinum shows promising efficacy in 1L ES-SCLC

Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Multiple myeloma in a resource constrained setting

ASCO GU 2024: Latest in PARP inhibitors for prostate cancer

Updates on lung cancer from WCLC and ESMO 2023

Subcutaneous delivery of nivolumab is effective in treating metastatic ccRCC

Cabozantinib and atezolizumab show more efficacy compared to second NHT in patients with mCRPC

Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy

CDK-4/6 inhibitors with endocrine treatment for metastatic breast cancer

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients